

Jean-Philippe Vuillez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3039158/publications.pdf>

Version: 2024-02-01

34
papers

1,107
citations

516710

16
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

1087
citing authors

#	ARTICLE	IF	CITATIONS
1	Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?. <i>Cancer Imaging</i> , 2020, 20, 58.	2.8	10
2	18F-Choline and 18F-FDG PET/CT in a Patient With Diffuse Large B-Cell Lymphoma and Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, e471-e472.	1.3	7
3	Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years. <i>Annals of Nuclear Medicine</i> , 2017, 31, 379-389.	2.2	1
4	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	4.6	33
5	Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1212-1217.	5.0	36
6	PET Adapted Salvage Therapy for Advanced Hodgkin Lymphomas: Towards the Suppression of Positive Interim PET Unfavorable Prognosis? a Report of the Goelams Multicentric Phase 2 Trial LH2007. <i>Blood</i> , 2015, 126, 3932-3932.	1.4	0
7	18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510.	6.4	14
8	Study of inter- and intra-observer reproducibility in the interpretation of [18F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment. <i>EJNMMI Research</i> , 2014, 4, 25.	2.5	9
9	Adjuvant Intraarterial Lipiodol or ¹³¹ I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. <i>Journal of Nuclear Medicine</i> , 2014, 55, 877-883.	5.0	17
10	Radioiodine therapy in benign thyroid disorders. Evaluation of French nuclear medicine practices. <i>Annales D'Endocrinologie</i> , 2014, 75, 241-246.	1.4	17
11	Nuclear medicine training and practice in France. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 976-978.	6.4	5
12	Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. <i>Immunotherapy</i> , 2013, 5, 1283-1286.	2.0	3
13	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1185-1192.	5.0	74
14	Reduction of renal uptake of ¹¹¹ In- ⁶⁷ Ge-DOTA-labeled and ⁷⁰⁰ keV-labeled ⁶⁷ Ge-RAFT- ⁶⁷ Ge-RGD during integrin $\alpha_5\beta_3$ targeting using single photon emission computed tomography and optical imaging. <i>Cancer Science</i> , 2012, 103, 1105-1110.	3.9	17
15	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. <i>Blood</i> , 2012, 120, 906-906.	1.4	5
16	18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours. <i>Nuclear Medicine Communications</i> , 2011, 32, 91-97.	1.1	15
17	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. <i>Blood</i> , 2010, 116, 2875-2875.	1.4	10
18	Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 758-764.	6.4	33

#	ARTICLE	IF	CITATIONS
19	Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2598-2600.	0.7	5
20	Chemical and Biological Evaluations of an ¹¹¹ In-Labeled RGD-Peptide Targeting Integrin Alpha(V) Beta(3) in a Preclinical Tumor Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 691-700.	1.0	18
21	Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4590-4597.	3.6	89
22	FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. <i>Brazilian Archives of Biology and Technology</i> , 2007, 50, 77-90.	0.5	10
23	In vivo imaging of tumour angiogenesis in mice with the ¹¹¹ In integrin-targeted tracer ^{99m} Tc-RAFT-RGD. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 2037-2047.	6.4	62
24	Sentinel lymph node biopsy in cutaneous melanoma: outcome after 5-years follow-up. <i>European Journal of Dermatology</i> , 2007, 17, 387-91.	0.6	6
25	Cellular uptake of ^{99m} TcN-NOET in human leukaemic HL-60 cells is related to calcium channel activation and cell proliferation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 66-72.	6.4	4
26	Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-CEA Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1705-1711.	1.6	231
27	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and ¹³¹ I-labeled bivalent hapten in a phase I optimization clinical trial. <i>Journal of Nuclear Medicine</i> , 2006, 47, 247-55.	5.0	88
28	Fluorinated tracers for imaging cancer with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1182-206.	6.4	116
29	Intrapleural Infusion of Activated Macrophages and ¹³ Interferon in Malignant Pleural Mesothelioma. <i>Chest</i> , 2002, 121, 1921-1927.	0.8	62
30	Pretargeting with the Affinity Enhancement System for Radioimmunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1999, 14, 153-166.	1.0	65
31	Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 8-11.	6.4	11
32	In-111 Pentetreotide Scintigraphy to Monitor Nonsecreting Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 1999, 24, 459-460.	1.3	0
33	Effects of preoperative intentional hemodilution on the extravasation rate of albumin and fluid. <i>Critical Care Medicine</i> , 1997, 25, 243-248.	0.9	29
34	Neopterin Levels in Plasma during a Longitudinal Study in an Area Endemic for Malaria. <i>Clinical Immunology and Immunopathology</i> , 1993, 67, 273-276.	2.0	5